EUROPEAN HEMATOLOGY

Letter

Clinical Significance of *TARP* Expression in Pediatric Acute Myeloid Leukemia

Barbara Depreter[1,2], Barbara De Moerloose[1,2,3], Karl Vandepoele[2,4], Anne Uyttebroeck[5], An Van Damme[6], Barbara Denys[4], Laurence Dedeken[7], Marie-Françoise Dresse[8], Jutte Van der Werff Ten Bosch[9], Mattias Hofmans[1,2], Tessa Kerre[2,10], Bart Vandekerckhove[2,11], Jan Philippé[2,4,11], Tim Lammens[1,2,3]

Correspondence: Tim Lammens (e-mail: tim.lammens@ugent.be).

Pediatric acute myeloid leukemia (pedAML) is a rare hematological disease accounting for 20% of all pediatric leukemias.[1] Current chemotherapeutic regimens have reached a survival plateau around 70%.[2,3] Still 30% to 40% of the good responders experience relapse, and especially patients with fms-like tyrosine kinase receptor-3 internal tandem duplications (*FLT3*-ITD) show a detrimental outcome.[2] These observations have driven the development of alternate therapeutic strategies, including targeting antibodies and chimeric antigen receptor (CAR)- or T-cell receptor (TCR)-

[1]*Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium*

[2]*Cancer Research Institute Ghent, Ghent, Belgium*

[3]*Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium*

[4]*Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium*

[5]*Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium*

[6]*Department of Pediatric Hematology Oncology, University Hospital Saint-Luc, Brussels, Belgium*

[7]*Department of Pediatric Hematology Oncology, Queen Fabiola Children's University Hospital, Brussels, Belgium*

[8]*Department of Pediatric Hematology Oncology, University Hospital Liège, Liège, Belgium*

[9]*Department of Pediatric Hematology Oncology, University Hospital Brussel, Brussels, Belgium*

[10]*Department of Hematology, Ghent University Hospital, Ghent, Belgium*

[11]*Department of Diagnostic Sciences, Ghent University, Ghent, Belgium*

transgenic cytotoxic T-cells (CTLs). However, besides *FLT3* inhibitor-based therapies[4,5] and CD33-directed agents,[6] targeted strategies have not yet found their way into treatment protocols.

We recently identified the TCR γ chain alternate reading frame protein (TARP) as an immunotherapeutic target in leukemic blasts (L-blast) and in leukemic stem cells (LSC) of adults and children with AML.[7] TARP was previously only reported in androgen-sensitive prostate and breast adenocarcinoma.[8]

Although *TARP* was upon its discovery described as a truncated TCRγ transcript encoding the first TCR γ chain constant domain (*TRGC1*), we found that an AML-exclusive, *TRGC2*-encoding *TARP* transcript co-exists in AML.[7] The high sequence homology between *TRGC1* and *TRGC2* hampers distinction through conventional techniques. Here, we used mRNA sequencing to demonstrate both *TARP* transcripts in four wild type (WT) AML cell lines with documented *TARP* expression.[7] We confirmed that *TRGC1* and *TRGC2* transcript are highly expressed in MV4;11, next to a moderate expression in HL-60 and THP-1, while negative in OCI-AML3 (Fig. S1A, http://links.lww.com/HS/A77). To gain insight into the biological relevance of both transcripts, transgenic TARP knockdown (TARP-KD) cell lines were generated for 2/4 AML cell lines, HL-60 and MV4;11, by retroviral transduction of TARP-targeting short-hairpin (shRNA) encoding viral particles, next to a mock construct.[7] In MV4;11, both *TRGC1* and *TRGC2* transcripts were suppressed upon *TARP* knockdown. In HL-60, only the *TRGC2* transcript was significantly downregulated compared to mock and WT, while *TRGC1* showed a two-fold decrease (Fig. S1B, Table S1, http://links.lww.com/HS/A77). Altogether, these data confirm that both *TRGC1*- and *TRGC2*-encoded *TARP* transcripts co-exist in AML cell lines, and are targetable.

Our previous data suggested that TARP peptides are adequately MHC-presented, as leukemic cells could be targeted *in vitro* by cytotoxic T-cells (CTLs) retrovirally transduced with a TCR directed against the HLA-A2 enhanced affinity TARP $(P5L)_{4-13}$ epitope.[7] However, whether recognition of tumor *TARP* peptide-MHC complexes (p-MHCs) by TCR-bearing CTLs is able to trigger antigen-specific immune responses *in vivo* still needs to be elucidated. To this end, TARP-TCR expression on CTLs isolated from pedAML patients was measured using HLA-A*0201-restricted, PE-conjugated tetramers directed against the TARP$(P5L)_{4-13}$ epitope, kindly provided by the NIH Tetramer Core Facility. Lymphocytes from *TARP*-high

Figure 1. Tetramer staining of TARP-TCR+ CTLs from pedAML patients. The lymphocyte gating strategy, described in Supplemental Materials, is illustrated in (A). The total lymphocyte compartment is indicated in green, other white blood cells in blue en non-viable cells or doublets in dark grey. Subsequent patient-individual gating of the CD3+/CD8+ compartment, and tetramer staining within this compartment, is shown for three *TARP*-high/HLA-A*0201 positive patients in (B-D). Tetramer-positive events, defining TARP-TCR+ CTLs, are indicated in black, and tetramer-negative CTLs in light grey. Non-CD3+/CD8+ cells within the lymphocyte gate are indicated in green. Median MFI values are indicated by circles. Tetramer positivity was gated for each patient individually based on sample-specific FMO controls. For two out of the three patients (B-C), both BM and PB were analysed. For one of the three patients (B), lymphocytes from both diagnosis and relapse could be evaluated. BM = bone marrow, CTL = cytotoxic T-cell, FMO = fluorescence-minus-one, PB = peripheral blood, TARP = T-cell receptor γ chain alternate reading frame protein, TCR = T-cell receptor.

(n = 5, 3/5 HLA-A*0201 positive) and *TARP*-low (n = 6, 5/6 HLA-A*0201 positive) pedAML patients were surface- and tetramer-stained and measured on a FACSCanto II flow cytometer (BD Biosciences).

All three *TARP*-high/HLA-A*0201-positive pedAML patients showed a positive tetramer staining within the CD3+/CD8+ compartment (median 2.4%, median MFI 357) (Fig. 1). MFI values were comparable between BM and PB as evaluated for 2/3 patients. TARP-TCR expression was higher at relapse compared to diagnosis in both PB and BM, as measured in one patient. Higher intensity tetramer staining can be associated with a higher TCR and/or co-receptor expression, and/or to a higher TCR avidity. This observation may relate to an achieved immunity for the tumor epitope, that is, the presence of resting CD8+ memory T-cells that rapidly reactivate and upregulate TCR expression upon p-MHC re-stimulation,[8] or the presence of a T-stem cell pool generated during the initial immune response.[9] If this hypothesis holds true, CTL priming by *TARP* vaccination after/during chemotherapy could be a therapeutic strategy. More diagnosis-relapse couples are needed to confirm this finding. Tetramer-positive CTLs from pedAML patients showed a fivefold lower TARP-TCR expression than the positive control (median MFI = 1793). No tetramer-positive population could be measured in the CTL compartment from *TARP*-high/HLA-A*0201 negative patients (n = 2), *TARP*-low/HLA-A*0201 positive patients (n = 5) or *TARP*-low/HLA-A*0201 negative (n = 1) patients.

Altogether, these data suggest that a pedAML patient's native immune response is triggered by HLA-presentation of *TARP* antigenic peptides in vivo, but, apparently insufficiently to

eradicate the leukemic cells. Both leukemic cell resistance and lymphocyte quiescence may account for this finding.[10] Also, due to T-cell ignorance, tumor-specific CTLs may be present but not primed by the antigen, or priming may be inefficient.[11] Gaining a deeper understanding of the underlying mechanisms may contribute to therapeutic targeting of TARP in pedAML.

We previously showed that *TARP* expression is associated with *FLT3*-ITD in pedAML. Unfortunately, the initial pediatric sample cohort was too small to evaluate a possible clinical impact of *TARP* expression. We here evaluated *TARP* expression in a larger cohort of LSC (n = 24) and L-blast (n = 29) cells sorted from pedAML patients using real-time quantitative PCR (qPCR), and compared expression levels to those measured in HSC (n = 25) and C-blast (n = 28) sorted from healthy controls. Data analysis is described in Supplemental, and expression values were expressed as calibrated normalised relative quantities (CNRQ).

A significantly increased *TARP* expression (p < .0001) was demonstrated in LSC and L-blast compared to their healthy counterparts (Fig. S2A, http://links.lww.com/HS/A77). PedAML patients were dichotomized as *TARP*-high (n = 13/29, 44.8%) and *TARP*-low (n = 16/29, 55.2%), using a cut-off based on the average expression measured in healthy controls plus 2 times the standard deviation (Table S2, http://links.lww.com/HS/A77). The presence of translocations, including core-binding factor leukemia, was significantly inversely correlated to *TARP* expression (p < .01 and < .0001, respectively). *FLT3*-ITD mutations (p < .0001) and HR profiles (p < .01) were exclusively observed in *TARP*-high patients (Fig. 2A). Within the *TARP*-high group, a significantly higher proportion of patients showed WBC

Figure 2. *TARP* transcript expression in pedAML in relation to subgroups and outcome. Correlation between patient characteristics and outcome between pedAML patients dichotomized as *TARP*-low (n = 16) and *TARP*-high (n = 13). *TARP* expression was measured by qPCR, and CNRQ values were interpreted against a cut-off calculated based on the expression in healthy controls (see Supplemental Materials, http://links.lww.com/HS/A77). p values <.05 were considered as significant. One, two, three or four asterisks are indicative for the level of significance (p < .05, p < .01, p < .001 and p < .0001, respectively). **(A)** Bars display the percentage of patients (%), harboring the characteristic shown in the x-axis, for *TARP*-high (black) and *TARP*-low (white) pedAML. The total number of patients positive for each characteristic is shown between parentheses. **(B)** Differential *TARP* expression between *FLT3*-ITD mutated and *FLT3* WT pedAML patients measured in the LSC and L-blast compartment. *FLT3*-ITD mutated pedAML showed a significantly higher *TARP* expression in both LSC (p < .0001) and L-blast (p < .0001). Thirteen out of the 29 pedAML patients were classified as *TARP*-high, that is, 11/11 *FLT3*-ITD pedAML and 2/18 *FLT3* WT pedAML (encoded by "18" and "25"). Horizontal bars indicate means, error bars indicate ±SEM, horizontal square brackets represent statistical comparisons and the dotted line represent the cut-off for elevated TARP expression. **(C-D)** Kaplan–Meier EFS and OS survival plots based on 15 pedAML treated in the NOPHO-DBH AML2012 protocol, dichotomized as TARP-high (n = 6, 4/6 *FLT3* ITD and 2/6 *FLT3* WT) or TARP-low (n = 9, 9/9 *FLT3* WT). The number of days is shown on the x-axis, and the percentage as a ratio (100% equals 1.0) on the y-axis. Drop-outs of the patients are indicated at the bottom per block of 250 days. **(C)** EFS was significantly lower in *TARP*-high versus *TARP*-low patients (16.7% vs 77.8%, respectively, p < .01). **(D)** OS was lower in *TARP*-high vs *TARP*-low patients (66.7% versus 88.9%, respectively), though at a non-significant level (p > .05). AK = abnormal karyotype, BM = bone marrow, *CEBPA* = CCAAT/enhancer-binding protein alpha, CNRQ = calibrated normalized relative quantity, CNS = central nerve system, F = female, FAB = French-British-American, *FLT3* = fms-like tyrosine kinase receptor-3, HR = high risk, ITD = internal tandem duplication, LSC = leukemic stem cell, L-blast = leukemic blast, M = male, MT = mutated, NK = normal karyotype, *NPM1* = nucleophosmin, PB = peripheral blood, PedAML = pediatric acute myeloid leukemia, qPCR = quantitative polymerase chain reaction, SEM = standard error of the mean, SR = standard risk, TARP = T-cell receptor γ chain alternate reading frame protein, *WT1* = Wilms' tumor 1, WBC = white blood cell, WT = wild type, yr = years.

counts $>30 \times 10^9$/L and blasts >70% in BM and >50% in PB (p < .05).

In concordance with our previous work, *TARP* transcript expression was significantly increased in LSC and L-blast (p < .0001) from *FLT3*-ITD pedAML (n = 11) compared to *FLT3* WT pedAML (n = 18) (Fig. 2B). Sixty-three percent of *FLT3*-ITD positive patients harbored a single ITD, 27% two ITDs and one patient presented four ITDs (Table S3, http://links.lww.com/HS/A77). The length of the duplicated region ranged between 20 and 96 base pairs (bp) (median 33 bp), and allelic ratios (ARs) varied from 2.7 to 70.8% (median 17.7%). There was no significant association between the number of

ITDs and the level of *TARP* expression. One patient presented only a single *FLT3*-ITD clone with an AR of 3.0%, but was still classified as *TARP*-high. Paired comparison of *TARP* expression measured in LSCs and L-blasts sorted from 9/11 *FLT3*-ITD mutated pedAML demonstrated a significantly higher expression in the latter compartment (p = .041, Fig. S2B, http://links.lww.com/HS/A77). This finding is in agreement with our published micro-array data of paired LSC and L-blast couples (GSE 128103).

Two *FLT3* WT pedAML patients showed elevated *TARP* expression in LSCs and L-blasts (pedAML18 and pedAML25). The presence of *TRGC* rearrangements, able to confound *TARP*

expression due to common TRGC coding regions and sporadically observed in AML,[12] was excluded. *FLT3*-ITD analysis was repeated on L-blast subpopulations to exclude a possible false negative result (not performed in LSC due to too low DNA concentration). One patient (pedAML18) harbored a rare *KMT2A-SEPT9* fusion protein, presented central nerve system (CNS) invasion and was classified as HR. The other patient showed a normal karyotype and *WT1* overexpression. Both *TARP*-high/*FLT3* WT patients with and without *KMT2A-SEPT9* relapsed after 8.4 months and presented with resistant disease, respectively. The first patient died 15.1 months after diagnosis.

Among NOPHO-DBH AML2012-treated patients (n=15), *TARP*-high pedAML (n=6) showed a significantly lower event-free survival (EFS) compared to *TARP*-low pedAML (n=9) (16.7% vs 77.8%, respectively, logrank p < .01, Fig. 2C). Relapse occurred in 3/6 *TARP*-high patients and 2/6 showed resistant disease, with an estimated time to event of 6.6 months. Two of the nine *TARP*-low patients also relapsed, with an estimated time to event of 34.6 months. Univariate Cox regression analysis confirmed this finding, showing a significant hazard ratio of 8.41 (95% confidence interval (CI) 1.52 – 46.6, p=.015) for the occurrence of an event in *TARP*-high patients. Multivariate analysis did not show an association between *TARP* expression and EFS (Table S4, http://links.lww.com/HS/A77). However, association with EFS did remain significant when including all diagnostic pedAML patients, irrespective of the treatment protocol (n=27/29, hazard ratio 3.83 (95% CI 1.1 – 13.0), p=.032). No significant correlation was found between the level of *TARP* expression and OS (hazard ratio 3.90 (95% CI 0.35–43.9), p=.27, Fig. 2D).

In conclusion, we here confirm that both *TRGC1-* and *TRGC2*-encoded *TARP* transcripts co-exist in AML. We demonstrate that TARP presentation on leukemic cells may induce beneficial immune responses in pedAML patients. We consolidate our previous finding that all *FLT3*-ITD positive pedAML patients display *TARP* overexpression, though also conclude that *TARP* overexpression is not exclusive for *FLT3*-ITD mutated patients. Furthermore, investigation on the role of FLT3 inhibitors in *TARP*-high pedAML patients, and their impact on *TARP* expression levels, is warranted. *TARP* expression was significantly inversely correlated with EFS in a small cohort of NOPHO-DBH AML2012-treated patients. The hypothesis that *TARP*−high/*FLT3*-WT pedAML patients may define a (till now undetectable) poor prognosis group with HR genetic lesions (*KMT2A-SEPT9*) and poor outcome will require further evaluation. Although promising, these data need confirmation in larger, preferably multicenter cohorts.

Disclosures

Acknowledgements

References

1. Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. *Leukemia.* 2018;32:2167–2177.
2. De Moerloose B, Reedijk A, de Bock GH, et al. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01. *Pediatr Blood Cancer.* 2019;66:e27605.
3. Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. *J Clin Oncol.* 2015;33:2949–2962.
4. Annesley CE, Brown P. The Biology and Targeting of FLT3 in Pediatric Leukemia. *Front Oncol.* 2014;4:263.
5. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? *Hematology Am Soc Hematol Educ Program.* 2013;2013:220–226.
6. Kaspers GJ. Pediatric acute myeloid leukemia. *Expert Rev Anticancer Ther.* 2012;12:405–413.
7. Depreter B, Weening KE, Vandepoele K, et al. TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment. *Haematologica.* 2019;Doi:10.3324/haematol.2019.222612.
8. Essand M, Vasmatzis G, Brinkmann U, et al. High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate. *Proc Natl Acad Sci U S A.* 1999;96:9287–9292.
9. Lefrancois L, Obar JJ. Once a killer, always a killer: from cytotoxic T cell to memory cell. *Immunol Rev.* 2010;235:206–218.
10. Gattinoni L, Speiser DE, Lichterfeld M, et al. T memory stem cells in health and disease. *Nat Med.* 2017;23:18–27.
11. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? *Curr Opin Immunol.* 2005;17:320–325.
12. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. *Nature Immunology.* 2013;14:1014–1022.